连续血清降钙素原水平对伴或不伴颅外损伤的创伤性脑损伤患者早期院内死亡率的预后价值:纵向观察性研究
该前瞻性观察性研究纳入186例年龄>18岁、存活至少12小时、入住一级创伤中心ICU的创伤性脑损伤患者,分为伴颅外损伤与不伴颅外损伤两组,按标准机构方案治疗,于入院时、第2天和第5天检测降钙素原水平。伴颅外损伤患者入院时、第2天、第5天降钙素原中位数分别为3.0、0.83、0.69 ng/ml。主要死亡率(中枢神经系统原因)为18例(9.7%),次要死亡率(脓毒症或颅外原因)为20例(12.3%)。回归分析显示入院时降钙素原>5.5 ng/ml预测主要中枢神经系统死亡的敏感度和特异度均为75%,第2天降钙素原>1.15 ng/ml预测次要(脓毒症)死亡的敏感度为70%、特异度为66%。ICU住院时间、格拉斯哥结局量表评分及主要/次要死亡率与是否伴颅外损伤无显著关联。结论认为降钙素原与伤后第1、2、5天结局相关性差,不支持其在该人群中用于结局(死亡率)评估的预后效用。
要点
- 在186例入住ICU的创伤性脑损伤患者中,第1、2、5天降钙素原水平与结局相关性差,结果不支持其用于预后评估。
- 伴颅外损伤患者入院时、第2天、第5天降钙素原中位数分别为3.0、0.83、0.69 ng/ml。
- 主要死亡率(中枢神经系统原因)为18例(9.7%),次要死亡率(脓毒症或颅外原因)为20例(12.3%)。
- 入院时降钙素原>5.5 ng/ml预测主要中枢神经系统死亡的敏感度和特异度均为75%;第2天降钙素原>1.15 ng/ml预测次要(脓毒症)死亡的敏感度为70%、特异度为66%。
- ICU住院时间、格拉斯哥结局量表评分及主要/次要死亡率与是否伴颅外损伤无显著关联。
适用人群与场景
- 年龄>18岁、存活至少12小时、入住一级创伤中心ICU的创伤性脑损伤患者,分为伴颅外损伤与不伴颅外损伤两组。
处置流程与药物剂量
- 所有入选患者均按标准机构方案治疗。
- 降钙素原水平于入院时、第2天和第5天检测。
研究设计与关键结果
- 研究类型为前瞻性纵向观察性研究,样本量186例,人群为入住一级创伤中心ICU的创伤性脑损伤患者,分为伴颅外损伤与不伴颅外损伤两组,所有患者按标准机构方案治疗。
- 伴颅外损伤患者入院时、第2天、第5天降钙素原中位数分别为3.0、0.83、0.69 ng/ml。
- 主要死亡率(中枢神经系统原因)为18例(9.7%),次要死亡率(脓毒症或颅外原因)为20例(12.3%)。
- 回归分析显示入院时降钙素原>5.5 ng/ml预测主要中枢神经系统死亡的敏感度和特异度均为75%;第2天降钙素原>1.15 ng/ml预测次要(脓毒症)死亡的敏感度为70%、特异度为66%。
- ICU住院时间、格拉斯哥结局量表评分及主要/次要死亡率与是否伴颅外损伤无显著关联。
证据类型、等级与局限
- 证据类型为前瞻性纵向观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究结果不支持降钙素原生物标志物用于伴或不伴颅外损伤的创伤性脑损伤患者结局(死亡率)评估的预后效用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Traumatic brain injury (TBI) is associated with majority of trauma deaths, and objective tools are required to understand the severity of injury. The application of a biomarker like procalcitonin (PCT) in TBI may allow for assessment of severity and thus aid in prognostication and correlation with mortality and outcome.
AIMS: The primary objective is to determine the correlation between PCT concentrations with TBI outcomes (mainly in terms of mortality) at intensive care unit (ICU)/hospital discharge. Secondary objectives are to evaluate correlation with associated extra cranial injuries and complications during hospital stay.
METHODS: In total, 186 TBI patients aged > 18 years with minimum survival for at least 12 h admitted to the ICU at the level 1 trauma center were prospectively included in the study and divided into two groups: TBI with and without extra cranial injuries. All admitted patients were treated according to the standard institutional protocol. The PCT levels were obtained on admission, on day 2, and 5. Clinical, laboratory, diagnostic, and therapeutic data were also collected. Primary mortality is defined as death related to central nervous system (CNS) injury, while secondary mortality defined as death related to sepsis or extracranial cause.
RESULTS: Median PCT levels at admission, day 2, and day 5 in TBI patients with extracranial injuries were 3.0, 0.83, and 0.69 ng/ml. In total, primary mortality was observed in 18 (9.7%) patients, while secondary causes were attributable in 20 (12.3%) patients. Regression analysis for primarily CNS cause of mortality showed PCT cutoff level at admission more than 5.5 ng/ml carried sensitivity and specificity of 75%, but for secondary cause (sepsis) of mortality, PCT cutoff values on day 2 > 1.15 ng/ml were derived significant with sensitivity of 70% and specificity of 66%. No significant association of parameters like length of ICU stay, Glasgow outcome scale (GOS), and primary/secondary mortality with the presence of extracranial injuries in TBI patients as compared with TBI alone was noted.
CONCLUSION: This observational study demonstrates the poor correlation between PCT concentrations with outcome at days 1, 2, and 5 post-injury. The predicted relationship between PCT levels and outcome was not confirmed, and that these results do not support the prognostic utility of PCT biomarker in this population for outcome (mortality) assessment in TBI patients with or without extracranial injuries.
参考来源
- Goyal K, Tomar GS, Sengar K, et al. Prognostic Value of Serially Estimated Serum Procalcitonin Levels in Traumatic Brain Injury Patients With or Without Extra Cranial Injury on Early In-hospital Mortality: A Longitudinal Observational Study. Neurocrit Care. 2021. PMID: 32533544. doi:10.1007/s12028-020-01009-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。